

## **LIFE: STRATEGIC COOPERATION TO MAKE GLUCOSE DATA MORE ACCESSIBLE**

**Bergen, Norway, August 13, 2024: Lifecare ASA, a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), is pleased to announce a strategic cooperation with OneTwo Analytics AB (OneTwo), a Swedish-based company specializing in data analytics of diabetes data.**

The strategic cooperation will provide Lifecare access to OneTwo's portfolio of comprehensive AI and ML based software for self-monitoring and automatic interpretation of CGM data. Furthermore, OneTwo will act as Lifecare's digital development partner on a consultancy base, as Lifecare intends to commercialize the software tool in the field of veterinary medicine on a license-base.

This marks a significant milestone in the advancement of veterinary medicine, aiming to bring cutting-edge analytical software developed for the human diabetes market to the veterinary field.

Under the terms of the strategic cooperation, OneTwo will leverage its expertise in data analytics and software development to create a digital infrastructure tailored to the needs of veterinary professionals. The centerpiece of this collaboration is OneTwo's "INSIGHTS and Clinic Portal" software.

Lifecare will take the lead in commercializing this advanced analytical software within the global veterinary market. The partnership grants Lifecare an exclusive, worldwide license to modify, market, and brand the software under its name. This software is designed to analyze glucose data from CGM sensors, providing critical insights into glucose deviations and fluctuations, which are vital for the diagnosis, treatment, and management of diabetes.

As part of the strategic cooperation, OneTwo will also develop a user-friendly mobile application compatible with both iOS and Android platforms. This app will facilitate seamless data transmission from the Sencell sensors to cloud servers and enable bi-directional communication with the customized analytical software. The digital infrastructure will not only serve the veterinary sector but also retain compatibility for potential human healthcare applications.

- Lifecare's vision has always been to make glucose monitoring easier for the patient using our Sencell sensor. In order to meet that customer promise, we must also be able to easily provide insight into valuable diabetes data through innovative and user-friendly software solutions, says Joacim Holter, CEO of Lifecare.

- We are thrilled to partner with OneTwo. This partnership underlines our commitment to promoting innovative technological solutions within diabetes monitoring and improving the health and well-being of patients worldwide, says Holter.

- Continuous monitoring of glucose levels entail large amounts of data for the clinicians and patients to interpret. Implementing AI/ML-based software to exploit and understand the amount of data is an absolute necessity. OneTwo's products are cutting edge, and this represents a significant strategic opportunity for us to introduce this, also in the veterinary market. In addition, we follow our overall strategy by introducing a uniform system that positions us for a later market launch in the human market, says Holter.

- This partnership is a natural extension of our mission to harness the power of data analytics for better health outcomes. By combining our technological expertise with Lifecare's market potential, we are poised to make a significant impact in both veterinary and human healthcare, says Lars Cederblad, co-founder and CEO of OneTwo Analytics AB.

OneTwo's development is rooted in scientific research by endocrinologists from Uppsala University and co-founders of OneTwo, Per-Ola Carlsson (MD, PhD, Professor) and Daniel Espes (MD, PhD, Assoc. Professor). The Swedish company's software is in compliance with the European Medical Device Directive/Medical Device Regulations and ISO 13485 and approved by the FDA for the US market.

OneTwo's software is implemented in Swedish and US health care clinics ensuring automated interpretation of CGM data. The software is compatible for automated interpretation of the CGM marked leaders Abbott and Dexcom sensors, of which OneTwo are engaged in a partnership with Dexcom for the Nordic and US market.

The parties have signed a Heads of Terms describing the strategic cooperation and will work closely together to finalize the agreement.

### **About us**

Lifecare ASA is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's main focus is to bring the next generation of Continuous Glucose Monitoring ("**CGM**") systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors ("**NTR**") on the sensor body for read-out of pressure variations. Lifecare's sensor technology is referred to as "Sencell" and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

### **Contacts**

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42



**PRESS RELEASE**  
13 August 2024 07:00:00 CEST

*This information has been submitted pursuant to the Securities Trading Act § 5-12 and MAR Article 19 no. 3. The information was submitted for publication at 2024-08-13 07:00 CEST.*